iVascular’s iCover Stent for Treatment of Iliac Lesions Evaluated in 1-Year ILICO Results

September 28, 2026—iVascular announced the presentation of the final 1-year results of the ILICO study evaluating the efficacy and safety of the company’s iCover covered stent for the treatment of de novo iliac atherosclerotic lesions in patients with symptomatic arteriopathy of the lower limbs.

The ILICO study is led by Coprincipal Investigators Professor Thomas Zeller, MD, and Professor Bahaa Nasr, MD. iVascular announced the initiation of the study in May 2022. The iCover covered stent received European CE Mark approval in March 2021.

Prof. Nasr presented the ILICO results at CIRSE 2026, the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe held in Copenhagen, Denmark.

According to the company, the prospective, multicenter, nonrandomized, single-arm observational study enrolled 232 patients across 18 sites in Germany, France, Belgium, and Spain. Follow-up is planned for up to 2 years.

The ILICO study’s primary endpoint is primary patency at 12 months. Secondary endpoints include freedom from all major adverse events, major amputation of the target limb, target lesion revascularization, target vessel revascularization, and quality of life.

The study included all types of iliac lesions, including the most complex ones: 30% of cases presented were TASC C and D lesions; 31% exhibited severe calcification; and 31% were completely occluded.

The company reported that at 1-year follow-up, iCover demonstrated efficacy in iliac arteries, including complex lesions, with 96.7% freedom from target lesion revascularization and 90.3% primary patency. Additionally, the device resulted in 100% technical success.

In iVascular’s press release, Prof. Nasr commented on the complexity of the treated lesions and the durability of the outcomes.

“These results are highly encouraging, particularly given the complexity of the iliac lesions treated compared with other covered stents trials,” stated Prof. Nasr. “Achieving 96.7% freedom from target lesion revascularization and 93.6% freedom from restenosis demonstrates the strong and durable performance of iCover, supporting its role as an effective solution for challenging iliac interventions.”